{"id":"NCT02260804","sponsor":"Celltrion","briefTitle":"To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma","officialTitle":"A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-09","primaryCompletion":"2018-01-04","completion":"2019-09-04","firstPosted":"2014-10-09","resultsPosted":"2021-04-08","lastUpdate":"2021-04-08"},"enrollment":258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Follicular Lymphoma"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P10","otherNames":[]},{"type":"BIOLOGICAL","name":"Rituxan","otherNames":[]}],"arms":[{"label":"CT-P10","type":"EXPERIMENTAL"},{"label":"Rituxan","type":"ACTIVE_COMPARATOR"}],"summary":"To demonstrate that CT-P10 is similar to Rituxan in terms of efficacy as determined by overall response rate at 7 months","primaryOutcome":{"measure":"Primary Efficacy Endpoint - Overall Response Rate by 7 Months","timeFrame":"During the Month 7 (up to Maintenance Cycle 3; Week 28)","effectByArm":[{"arm":"CT-P10","deltaMin":108,"sd":null},{"arm":"Rituxan","deltaMin":104,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["34686445","30389036"],"seeAlso":["http://www.celltrion.com"]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":130},"commonTop":["Infusion related reaction","Upper respiratory tract infection","Fatigue","Urinary tract infection","Cough"]}}